Axsome Therapeutics (AXSM) Misses Q2 EPS by 14c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.99), $0.14 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $218.37 million versus the consensus estimate of $221.92 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral